Trudy McGarry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Trudy McGarry has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alice M. Walsh
Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA
1 shared publication - Barry Moran
School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland
1 shared publication - Carl Orr
Centre for Arthritis and Rheumatic Diseases, Saint Vincent's University Hospital, Dublin, Ireland
1 shared publication - Douglas James Veale
EULAR Centre of Excellence, Centre for Arthritis and Rheumatic Diseases, St Vincent’s University Hospital, Dublin, Ireland
1 shared publication - Hannah Convery
Centre for Arthritis & Rheumatic Diseases, St. Vincent’s University Hospital, University College Dublin, Ireland
1 shared publication - Jean M. Fletcher
School of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 6 December 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (23)
Enriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis
CD141 + DC are implicated in antiviral and antitumor immunity. However, mechanistic studies in autoimmune disease are limited. This is the first study to our knowledge examining CD141 + DC in autoimmune disease, specifically inflammatory arthritis (IA). We identified significant enrichment of CD141 + DC in the inflamed synovial joint, which were transcriptionally distinct from IA and healthy control (HC) blood CD141 + DC and significantly more activated, and they exhibited increased responsiveness to TLR3. Synovial CD141 + DC represent a bone fide CD141 + DC population that is distinct from CD1c + DC. Synovial CD141 + DC induced higher levels of CD4 + and CD8 + T cell activation compared with their peripheral blood counterparts, as made evident by expression of IFN-γ, TNF-α, and granulocyte-macrophage CSF (GMCSF). Autologous synovial CD141 + DC cocultures also induce higher levels of these cytokines, further highlighting their contribution to synovial inflammation. Synovial CD141 + DC–T cell interactions had the ability to further activate synovial fibroblasts, inducing adhesive and invasive pathogenic mechanisms. Furthermore, we identify a mechanism in which synovial CD141 + DC are activated, via ligation of the hypoxia-inducible immune-amplification receptor TREM-1, which increased synovial CD141 + DC activation, migratory capacity, and proinflammatory cytokines. Thus, synovial CD141 + DC display unique mechanistic and transcriptomic signatures, which are distinguishable from blood CD141 + DC and can contribute to synovial joint inflammation.
- 6 December 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (23)
Open AccessEnriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis
CD141 + DC are implicated in antiviral and antitumor immunity. However, mechanistic studies in autoimmune disease are limited. This is the first study to our knowledge examining CD141 + DC in autoimmune disease, specifically inflammatory arthritis (IA). We identified significant enrichment of CD141 + DC in the inflamed synovial joint, which were transcriptionally distinct from IA and healthy control (HC) blood CD141 + DC and significantly more activated, and they exhibited increased responsiveness to TLR3. Synovial CD141 + DC represent a bone fide CD141 + DC population that is distinct from CD1c + DC. Synovial CD141 + DC induced higher levels of CD4 + and CD8 + T cell activation compared with their peripheral blood counterparts, as made evident by expression of IFN-γ, TNF-α, and granulocyte-macrophage CSF (GMCSF). Autologous synovial CD141 + DC cocultures also induce higher levels of these cytokines, further highlighting their contribution to synovial inflammation. Synovial CD141 + DC–T cell interactions had the ability to further activate synovial fibroblasts, inducing adhesive and invasive pathogenic mechanisms. Furthermore, we identify a mechanism in which synovial CD141 + DC are activated, via ligation of the hypoxia-inducible immune-amplification receptor TREM-1, which increased synovial CD141 + DC activation, migratory capacity, and proinflammatory cytokines. Thus, synovial CD141 + DC display unique mechanistic and transcriptomic signatures, which are distinguishable from blood CD141 + DC and can contribute to synovial joint inflammation.